Clinical trials: CD8+ Tumor Infiltrating Lymphocytes
Breast Cancer, Estrogen Receptor Positive Tumor
Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor).
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, Menopause, Hormone Antagonist
- Trial name
- ULTIMATE (NCT02997995)
- Testing
- Immune-attractant, Durvalumab, Biopsy
- Where
- 29 sites in France, Spain and 1 more
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Lung Cancer, Non Small Cell Lung Cancer
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify…
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06863233
- Testing
- Zirconium Zr 89 crefmirlimab berdoxam, PET/CT Scan
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Early Breast Cancer
The Prognostic Role of TILs and CD8+ T Cells in Operable Breast Cancer
T cells are a broad class of adaptive immune cells, while CD8⁺ T cells are a specific, specialized subset of T cells, defined by the presence of the CD8 surface receptor.
- Trial name
- Ν/Α (NCT07545434)
- Where
- Greece
- Volunteers
- 3,646 people
- Sponsor
- Hellenic Cooperative Oncology Group
Skin Cancer, Metastatic Melanoma
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Background: One experimental treatment for certain types of cancer is cell therapy, which involves collecting lymphocytes (white blood cells) from a tumor, growing them in the laboratory in large numbers, and then modifying the…
- Trial name
- NCT01236573
- Testing
- Fludarabine, Cyclophosphamide, IL-12 transduced TIL
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a…
- Trial name
- NCT06052839
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dan Zandberg
Tumor Infiltrating Lymphocyte, CD8-PET
Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With
To find out if the amount of CD8 immune cells at the place where TIL cells are collected is linked to how well a patient responds to treatment.
- Conditions
- Tumor Infiltrating Lymphocyte, CD8-PET, Advanced Melanoma
- Trial name
- NCT07819474
- Testing
- Crefmirlimb, PET/CT imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor Malignancy
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy and in combination with anti programmed cell…
- Trial name
- CICILIA (NCT04260529)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 8 sites in France, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Cytovation AS
Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes
Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with…
- Conditions
- Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes, Neoadjuvant Immunotherapy
- Trial name
- NCT05270824
- Testing
- radical surgery after neoadjuvant immunotherapy, radical surgery after neoadjuvant chemotherapy
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Breast Cancer
Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy
Neoadjuvant chemotherapy is standard therapy for the management of localised breast cancer, and makes it possible to evaluate tumour response.
- Trial name
- PRIMUNEO (NCT01513408)
- Testing
- immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Georges Francois Leclerc